WAVE Life Sciences Ltd.
WVE
$5.65
$0.173.10%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 83.75M | -7.68M | 19.69M | 12.54M | 29.06M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 83.75M | -7.68M | 19.69M | 12.54M | 29.06M |
| Cost of Revenue | 44.65M | 41.20M | 40.39M | 33.45M | 34.07M |
| Gross Profit | 39.10M | -48.87M | -20.70M | -20.91M | -5.02M |
| SG&A Expenses | 16.14M | 15.04M | 14.30M | 13.55M | 13.66M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 60.78M | 56.24M | 54.69M | 47.00M | 47.74M |
| Operating Income | 22.97M | -63.92M | -35.00M | -34.46M | -18.68M |
| Income Before Tax | 29.25M | -61.78M | -32.92M | -31.56M | -16.26M |
| Income Tax Expenses | -- | -- | -- | -- | 0.00 |
| Earnings from Continuing Operations | 29.25M | -61.78M | -32.92M | -31.56M | -16.26M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 29.25M | -61.78M | -32.92M | -31.56M | -16.26M |
| EBIT | 22.97M | -63.92M | -35.00M | -34.46M | -18.68M |
| EBITDA | 23.87M | -62.97M | -34.00M | -33.42M | -17.60M |
| EPS Basic | 0.18 | -0.47 | -0.25 | -0.24 | -0.15 |
| Normalized Basic EPS | 0.11 | -0.29 | -0.16 | -0.15 | -0.09 |
| EPS Diluted | 0.17 | -0.47 | -0.25 | -0.24 | -0.15 |
| Normalized Diluted EPS | 0.11 | -0.29 | -0.16 | -0.15 | -0.09 |
| Average Basic Shares Outstanding | 161.49M | 132.56M | 129.53M | 129.27M | 109.63M |
| Average Diluted Shares Outstanding | 172.29M | 132.56M | 129.53M | 129.27M | 109.63M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
